All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Are peptide side effects really 'self-inflicted'? Let's check the data

JoshTides

TikTok creator

1.5K viewsWatch on TikTok→

Quick answer

Retatrutide is a triple receptor agonist (GLP-1, GIP, glucagon) in Phase 3 clinical trials as of 2024, with no current FDA approval. The creator's advice that nausea correlates with rapid dose escalation is consistent with structured titration protocols used in the Jastreboff et al. 2023 NEJM Phase 2 trial. However, muscle preservation during Retatrutide-assisted weight loss requires protein intake optimization alongside resistance training, a point the video omits entirely.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.

What did @joshtides actually say?

The creator argues that most side effects from Retatrutide ("Retta") are the user's own fault. Specifically, he links low energy to inadequate food intake, nausea to dosing too fast, and muscle loss to skipping the gym. His framing: fix your habits, fix your side effects.

This is a fairly common line of thinking in the peptide and GLP-1 analog community, and it isn't entirely without merit. But calling side effects "self-inflicted" flattens a genuinely complicated picture. Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Its side effect profile isn't simply a lifestyle report card. Some of what he describes is real. Some of it is missing important context.

Does the science back this up?

Partly. The nausea and dosing relationship has solid support. The energy and muscle-loss advice is grounded in real physiology, but oversimplified.

The Phase 2 trial published by Jastreboff et al. (2023, NEJM) showed that nausea was the most common adverse event in Retatrutide groups, occurring in 40-45% of participants at higher doses. Crucially, that trial used structured dose escalation specifically to minimize GI side effects. Rushing dose increases does make nausea worse, and that part of @joshtides' advice tracks with the clinical approach.

On energy: GLP-1 receptor agonists reduce caloric intake significantly. Heymsfield et al. (2021, Obesity Reviews) documented that very low energy availability during GLP-1-driven weight loss can impair thyroid function and reduce resting metabolic rate. Telling people to eat more carbs isn't wrong, but "eat more food" without any qualifier about protein targets misses the biggest lever.

On muscle loss: resistance training does preserve lean mass during caloric restriction. Barakat et al. (2020, Strength and Conditioning Journal) confirmed this. But Retatrutide's glucagon agonism adds a metabolic wrinkle that "hit the gym more" doesn't fully address.

What did they get wrong (or right)?

He got the nausea-dosing connection right. That one is well-supported. Where things get shaky is the framing that side effects are primarily "based off of your habits."

GI side effects from triple agonists like Retatrutide have a pharmacological basis that exists independent of user behavior. The Jastreboff 2023 trial saw nausea in a controlled clinical population following a precise protocol. These weren't people skipping meals or slamming doses. The side effects happened anyway, just less severely than with rapid escalation.

The muscle loss point deserves more than "hit the gym." Retatrutide's glucagon component increases fatty acid oxidation but also raises protein turnover. Without adequate dietary protein, exercise alone is insufficient. Carbone et al. (2019, Nutrients) found protein intake of at least 1.6g per kg body weight was necessary to preserve lean mass during a caloric deficit. He mentions carbs but not protein. That's a significant omission when you're recommending how to protect muscle on a potent GLP-1 triple agonist.

To his credit, he does not claim Retatrutide treats any disease, and he doesn't give a specific dose recommendation. That keeps the video cleaner than most in this space.

What should you actually know?

Retatrutide is not an approved drug. As of mid-2024, it remains in Phase 3 trials. Any version being discussed in the peptide community is a research chemical or compounded product, and those carry additional variables including purity, concentration accuracy, and sterility that clinical trial participants do not face.

Side effect management on unapproved compounds is also not the same as following a studied protocol. The titration schedules in the Jastreboff trial were supervised. Applying the general logic of "slow down your dose" without medical supervision is reasonable general advice, but it isn't a substitute for clinical guidance.

Low energy on any GLP-1-class compound is a real signal worth taking seriously. It can indicate inadequate total caloric intake, but it can also reflect electrolyte imbalance, particularly sodium and potassium, which is common during rapid weight loss. Attributing it entirely to "you need to eat more food" may cause someone to ignore a different problem.

If you are using or considering Retatrutide, work with a licensed provider who can monitor labs, adjust dosing, and catch side effects that have nothing to do with your gym schedule.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 10 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Are peptide side effects really 'self-inflicted'? Let's check the data, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Are peptide side effects really 'self-inflicted'? Let's check the data is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

Compare providers, services and access requirements in the directory before contacting a suitable care team.

Claim verdict

The useful answer behind this video

Claim being checked

Retatrutide is a triple receptor agonist (GLP-1, GIP, glucagon) in Phase 3 clinical trials as of 2024, with no current FDA approval.

FormBlends verdict

Retatrutide is a triple receptor agonist (GLP-1, GIP, glucagon) in Phase 3 clinical trials as of 2024, with no current FDA approval. The creator's advice that nausea correlates with rapid dose escalation is consistent with structured titration protocols used in the Jastreboff et al. 2023 NEJM Phase 2 trial. However, muscle preservation during Retatrutide-assisted weight loss requires protein intake optimization alongside resistance training, a point the video omits entirely.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Retatrutide is a triple receptor agonist (GLP-1, GIP, glucagon) in Phase 3 clinical trials as of 2024, with no current FDA approval. The creator's advice that nausea correlates with rapid dose escalation is consistent with structured titration protocols used in the Jastreboff et al. 2023 NEJM Phase 2 trial. However, muscle preservation during Retatrutide-assisted weight loss requires protein intake optimization alongside resistance training, a point the video omits entirely.
  • Retatrutide has no FDA approval as of 2024. Any version circulating in the peptide market is a research chemical or compounded product, not a tested pharmaceutical.
  • The Jastreboff et al. 2023 NEJM Phase 2 trial showed nausea in 40-45% of participants at higher doses even under controlled, supervised titration protocols.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Retatrutide has no FDA approval as of 2024. Any version circulating in the peptide market is a research chemical or compounded product, not a tested pharmaceutical.
  • The Jastreboff et al. 2023 NEJM Phase 2 trial showed nausea in 40-45% of participants at higher doses even under controlled, supervised titration protocols.
  • Slow dose escalation does reduce GI side effects with GLP-1-class compounds. This is standard practice in clinical protocols and the creator's advice here is directionally correct.
  • Muscle preservation during aggressive caloric restriction requires protein intake of at least 1.6g per kg body weight (Carbone et al., 2019, Nutrients). Exercise alone is not enough without adequate protein.
  • Low energy during GLP-1-driven weight loss can reflect electrolyte imbalance (sodium, potassium) in addition to low caloric intake. Eating more carbs does not address electrolyte depletion.
  • Retatrutide's glucagon receptor agonism distinguishes it from simpler GLP-1 analogs and adds metabolic effects, including increased protein turnover, that lifestyle advice alone does not fully counteract.
  • Side effect management on unapproved compounds is not equivalent to following a supervised clinical protocol. A licensed provider should monitor labs and dosing adjustments.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

JoshTides · TikTok creator

1.5K views on this video

your side effects are self inflicted #biohacking

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by JoshTides, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.